Amyloid β aggregates in cerebrospinal fluid as a biomarker for Alzheimer's disease

摘要

And a step of obtaining a measurement of Aβ40 aggregates in a biological sample of a subject, said biological sample is brain tissue, not intended to include a brain homogenate or fractions of brain tissue, the present invention is evaluated I will provide a method of evaluating the probability that increased with Alzheimer's disease in a subject of. In some embodiments, the present invention relates to a method for evaluating the probability of increased early Alzheimer's disease stages. The present invention, further, how to specify the disease stage of the subject of the Alzheimer's Disease Assessment method of the probability that no increase in Alzheimer's disease, and monitoring methods, the disease progression in a subject of Alzheimer's disease and MCI is Alzheimer's disease I will provide a method of evaluating the probability increased to progress.